Navigation Links
AANMA Announces Launch of Free Web-Based Education Program for Patients Transitioning From CFC to HFA Inhalers
Date:12/3/2008

FAIRFAX, Va., Dec. 3 /PRNewswire-USNewswire/ -- Allergy & Asthma Network Mothers of Asthmatics (AANMA) announced today that a new Web-based video geared to help people successfully manage the transition from CFC albuterol inhalers to HFA inhalers is now available at its Web site, www.breatherville.org. Smart Moves to an HFA Inhaler uses technology that allows viewers to ask questions in everyday language and immediately receive a response with relevant, highly focused answers. Users can obtain valuable information about why inhalers are changing, the differences between newer and older inhalers, cost concerns and how to use new HFA inhalers.

"We created this video to help patients and their families learn more about this federal mandate, as a significant number of patients are still not aware of how to safely go about making this change," said Nancy Sander, president and founder of AANMA. "At the end of the year, inhalers are changing. These changes are mandatory, and there are important decisions to make about treatment options that require thoughtful consideration of the patient's medical history and current respiratory health status."

In less than 30 days, life-saving albuterol inhalers used by nearly 40 million patients with respiratory disorders will no longer be sold. After December 31, 2008, it will no longer be permissible to manufacture or sell albuterol inhalers in the United States that contain chlorofluorocarbon (CFC) propellants, because they destroy the Earth's ozone layer. These inhalers have been replaced with four distinct non-CFC propelled alternatives, which contain hydrofluoroalkane (HFA) propellant.

While the transition has been forthcoming for some time, data from IMS Health show that an estimated 14 million CFC prescriptions have yet to be transitioned to HFA MDIs.(1) The absence of a medically responsible transition protocol leaves patients unknowingly exposed to health risks beyond their control.

Patients with asthma, COPD and other respiratory conditions use albuterol at the first sign of symptoms, before exercise and when experiencing breathing exacerbations. Because there are significant differences between CFC and HFA inhalers, patients and medical professionals need to have the opportunity to make the switch in a medically responsible way.

The Web module is hosted by former CNN Medical correspondent Rea Blakey, and supported by an educational grant from Sepracor.

For more information about the MDI transition, please visit AANMA's MDI Transition Web page at www.mditransition.org. Patients seeking information can also call AANMA's Patient Support Center at 800-315-8056.

About AANMA

Founded in 1985, Allergy & Asthma Network Mothers of Asthmatics is the leading national nonprofit family organization dedicated to eliminating suffering and death due to asthma, allergies and related conditions. AANMA's core areas of expertise are education, advocacy and outreach. Call 800.878.4403 or visit www.breatherville.org.

(1) IMS NPA, August 22, 2008


'/>"/>
SOURCE Allergy & Asthma Network Mothers of Asthmatics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lucas Group Announces Their Executive Recruitment Military Hiring Conference Schedule for December 2008
2. Axiom Consulting Partners Announces the Results of its Return On Sales Investment Survey
3. United American Healthcare Corporation Announces Stock Repurchase Program
4. eOn Communications Announces GSA Contract
5. Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
6. USHIFU Announces First Sonablate(R) HIFU Device in India for Minimally Invasive Prostate Cancer Treatment
7. Elsevier announces the 2008 supplement of Reproductive Health Matters
8. Pascal Metrics Announces Patient Safety Culture Services Offering
9. Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology
10. Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial
11. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... ... examination of how God handles sin, including how to let go of lingering guilt and ... ten long years has been waiting to release this powerful insight about forgiveness that the ... the Lord for over twenty years, and he has been preaching and teaching the Word ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Land of More and More”: ... issue of world hunger, and shares the simple and achievable answer. “The Land of ... member of the Fairview Missionary Church in Angola, Indiana where he works with the ...
(Date:1/19/2017)... ... January 19, 2017 , ... Wells ... facility enhancement of their 503A compounding pharmacy located in Ocala, Florida. , ... physicians and patients throughout the United States for high-quality human anti-aging and ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... telemedicine solutions, has recently unveiled impressive transportable capabilities with their iMedHD2™ Portable ... is an extension to RMT technology that delivers HD, dynamic, streaming ultrasound images ...
(Date:1/19/2017)... ... January 19, 2017 , ... MB Business Capital, ... $11,250,000 senior credit facility to Sunrise, Florida-based Management Health Systems, LLC, dba MedPro ... facilitate a recapitalization of MedPro led by Harren Equity Partners. Brightwood Capital ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... ALTO, Calif. , Jan. 19, 2017   ... research, is excited to announce that the first ... Cancer Biology  (RP:CB) have been published in eLife ... this project represents the first practical evaluation of ... result in reproducible studies. Unlike other assessments of ...
(Date:1/19/2017)... Marks E-QURE , s 3 ... agreements in Israel and Argentina ... billion global market ... devices for the treatment of advanced wound care, announced today it signed a ... Colombia for the Company,s patented Bio-electrical Signal Therapy device ("BST Device"), ...
(Date:1/19/2017)... The drug delivery technology market is projected ... 1,179.20 billion in 2016, at a CAGR of 7.2% ... diseases, increasing demand for biologics, technological advancements, and new ... this market. Whereas, self-administration & home care and rising ... opportunities for players operating in this market. On the ...
Breaking Medicine Technology: